Literature DB >> 32818245

Cutting not the key to TMPRSS6 activity?

Thomas Benedict Bartnikas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32818245      PMCID： PMC7441165          DOI： 10.1182/blood.2020006608

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.

Authors:  Carla Casu; Mariam Aghajan; Paraskevi Rea Oikonomidou; Shuling Guo; Brett P Monia; Stefano Rivella
Journal:  Haematologica       Date:  2015-09-24       Impact factor: 9.941

2.  The ectodomain of matriptase-2 plays an important nonproteolytic role in suppressing hepcidin expression in mice.

Authors:  Caroline A Enns; Shall Jue; An-Sheng Zhang
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

3.  RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.

Authors:  Paul J Schmidt; Kaifeng Liu; Gary Visner; Kevin Fitzgerald; Shannon Fishman; Tim Racie; Julia L Hettinger; James S Butler; Mark D Fleming
Journal:  Am J Hematol       Date:  2018-03-23       Impact factor: 10.047

4.  An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Authors:  Paul J Schmidt; Iva Toudjarska; Anoop K Sendamarai; Tim Racie; Stuart Milstein; Brian R Bettencourt; Julia Hettinger; David Bumcrot; Mark D Fleming
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

5.  Discovery and Development of TMPRSS6 Inhibitors Modulating Hepcidin Levels in Human Hepatocytes.

Authors:  François Béliveau; Aarti Tarkar; Sébastien P Dion; Antoine Désilets; Mariana Gabriela Ghinet; Pierre-Luc Boudreault; Catherine St-Georges; Éric Marsault; Daniel Paone; Jon Collins; Colin H Macphee; Nino Campobasso; Arthur Groy; Josh Cottom; Michael Ouellette; Andrew J Pope; Richard Leduc
Journal:  Cell Chem Biol       Date:  2019-09-19       Impact factor: 8.116

6.  Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.

Authors:  Shuling Guo; Carla Casu; Sara Gardenghi; Sheri Booten; Mariam Aghajan; Raechel Peralta; Andy Watt; Sue Freier; Brett P Monia; Stefano Rivella
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

7.  Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.

Authors:  Paul J Schmidt; Tim Racie; Mark Westerman; Kevin Fitzgerald; James S Butler; Mark D Fleming
Journal:  Am J Hematol       Date:  2015-04       Impact factor: 10.047

Review 8.  Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis.

Authors:  Zachary J Hawula; Daniel F Wallace; V Nathan Subramaniam; Gautam Rishi
Journal:  Pharmaceuticals (Basel)       Date:  2019-11-25

Review 9.  Iron metabolism and iron disorders revisited in the hepcidin era.

Authors:  Clara Camaschella; Antonella Nai; Laura Silvestri
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

10.  SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1.

Authors:  Sandro Altamura; Ute Schaeper; Sibylle Dames; Kathrin Löffler; Mona Eisermann; Christian Frauendorf; Katja Müdder; Joana Neves; Martina U Muckenthaler
Journal:  Hemasphere       Date:  2019-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.